Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Exploring the Interplay Between Maternal Stress, Human Milk, and Epigenetic Changes in Preterm Infant's Neurodevelopment (EMBRACE)

11 de noviembre de 2026 actualizado por: Camilla Fontana, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Preterm birth represents a major challenge in pediatric healthcare, as preterm infants are at increased risk of neonatal complications and long-term neurodevelopmental impairments. Several factors may contribute to these outcomes, including gestational age at birth, postnatal comorbidities, and the neonatal intensive care unit (NICU) environment. Furthermore, preterm birth and prolonged hospitalization may negatively affect maternal psychological well-being, increasing the risk of stress, anxiety, and depression. These conditions may influence maternal sensitivity and responsiveness, mother-infant interactions, and infant neurodevelopment.

Emerging evidence suggests that maternal mental health may affect infant neurodevelopment through both direct biological mechanisms, such as epigenetic regulation, and indirect pathways, including changes in breast milk composition. Cortisol, a stress-related hormone present in breast milk and saliva, may play a role in stress regulation and neurobehavioral development. In particular, the methylation of Long Interspersed Nuclear Element-1 (LINE-1 or L1), a mobile genetic element involved in genomic regulation, may be influenced by environmental factors and early maternal care. Preliminary findings indicate that preterm infants exhibit lower L1 promoter methylation levels at birth than term infants, while early maternal care may modulate these levels and support neurobehavioral development.

The EMBRACE study aims primarily to investigate the relationship between biological maternal stress, measured through salivary cortisol levels, and L1 promoter methylation in blood samples collected from preterm infants from birth to 12 months of corrected age. Secondary objectives include examining this relationship in buccal swab samples, assessing associations between maternal perceived stress, anxiety, and depression and infant L1 methylation, and investigating the relationship between maternal psychological and biological stress indicators and infant neurodevelopmental outcomes. The study will also explore associations between perceived maternal stress and cortisol concentrations in breast milk and saliva, as well as longitudinal changes in L1 methylation.

This is a non-pharmacological, observational cohort study conducted at the Neonatology and Neonatal Intensive Care Unit of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy. Participants will include preterm infants born between 24+0 and 30+6 weeks of gestational age and their mothers. Assessments will be conducted at five time points: birth, transition to intermediate care or 34 weeks of postmenstrual age, hospital discharge, 6 months, and 12 months of corrected age. Maternal assessments will include standardized questionnaires evaluating stress, anxiety, and depression, as well as cortisol measurements in saliva and breast milk. Infant assessments will include L1 methylation analyses in blood and buccal samples and standardized neurodevelopmental evaluations as part of routine clinical follow-up. No additional invasive procedures will be performed, as blood samples will be collected during routine clinical care.

The study is expected to improve understanding of the relationships between maternal stress, anxiety, depression, epigenetic regulation, and neurodevelopment in preterm infants. It will also investigate the potential role of breast milk cortisol in these associations. Ultimately, the findings may contribute to the development of early interventions aimed at improving neurodevelopmental outcomes in preterm infants and supporting maternal psychological well-being.

Descripción general del estudio

Estado

Reclutamiento

Tipo de estudio

De observación

Inscripción (Estimado)

96

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Lombardy
      • Milan, Lombardy, Italia, 20122
        • Reclutamiento
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
        • Contacto:
        • Sub-Investigador:
          • Chiara Bonfanti
        • Sub-Investigador:
          • Agnese De Carli
        • Sub-Investigador:
          • Monica Fumagalli
        • Sub-Investigador:
          • Mary Giorgia Gaccione

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

5 meses a 6 meses (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

All preterm infants born at the SC Neonatologia e Terapia Intensiva Neonatale - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano and their mothers.

Descripción

Inclusion Criteria:

  • Preterm infants born between 24+0 and 30+6 weeks of gestational age (GA);
  • Mothers aged ≥ 18 years with adequate understanding of the Italian language;
  • Signed informed consent from parents.

Exclusion Criteria:

  • Parents decline participation;
  • Infants with major congenital anomalies, malformations, or genetic syndromes;
  • Mothers with obvious psychiatric conditions, cognitive deficits, or active substance abuse at the time of delivery.
  • Infants birth samples not available (both buccal swab and blood)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Epigenetic changes on LINE1 (blood samples)
Periodo de tiempo: up to 48 weeks post menstrual age

epigenetic analysis is performed on cord blood samples collected at birth, at transition to intermediate care and at hospital discharge on peripheral blood samples

up to 48 weeks post menstrual age
Maternal salivary cortisol
Periodo de tiempo: up to 12 months corrected age of the infant

Collected at birth, transition to intermediate care, discharge

up to 12 months corrected age of the infant

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Human milk cortisol concentrations
Periodo de tiempo: up to 6 months corrected age of the infant

Collected at birth, transition to intermediate care, discharge

up to 6 months corrected age of the infant
Buccal swab
Periodo de tiempo: up to 12 months corrected age

Collected at birth, 34 weeks GA, discharge, 6 and 12 months corrected age

up to 12 months corrected age
Neurological outcome
Periodo de tiempo: up to 44 weeks post menstrual age

Hammersmith neonatal neurological examination performed at NICU discharge

up to 44 weeks post menstrual age
Neonatal Visual Assessment
Periodo de tiempo: up to 44 weeks post menstrual age

Neonatal visual function in assessed at discharge using the Visual Assessment battery developed by Ricci et al. The assessment has 9 items and each one is scored as normal or abnormal according to the description given by the authors.

up to 44 weeks post menstrual age
Neonatal behavior
Periodo de tiempo: up to 44 weeks post menstrual age

Neonatal behavior is assessed using the Neonatal Behavior Assessment Scale, and in particular the areas of state organization, state regulation, and the autonomic system. Each item will be scored according to the description given by the author of the assessment

up to 44 weeks post menstrual age
Neurodevelopmental outcome
Periodo de tiempo: from 6 to 12 months corrected age

Bayley scales to assess neurodevelopment at 6 and 12 months corrected age. The normal range for the composite score is 100 +/- 15 points. Higher scores mean better outcomes.

from 6 to 12 months corrected age
Maternal depression
Periodo de tiempo: up to 12 months corrected age of the infant

Assessed with the Edinburgh Postnatal depression scale. Responses are scored 0 to 3. A score above 8 is considered pathological in the post partum period. It will be administered at birth, at transition to intermediate care, at NICu discharge at 6 and 12 months corrected age.

up to 12 months corrected age of the infant
Maternal stress in the NICU
Periodo de tiempo: up to 12 months corrected age of the infant

Assessed with the Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU). It is composed of 35 items that are scored on a 5-point Likert scale ranging from 1 (not stressful at all) to 5 (extremely stressfull). It will be administered at birth, at transition to intermediate care and at NICu discharge.

up to 12 months corrected age of the infant
Maternal bonding
Periodo de tiempo: up to 12 months corrected age of the infant

Assessed with the Postpartum Bonding Questionnaire (PBQ) administered at NICU discharge, 6 and 12 months corrected age. A score above 26 is considered pathological.

up to 12 months corrected age of the infant
Maternal anxiety and depression
Periodo de tiempo: up to 12 months corrected age of the infant

Assessed with the hospital anxiety and depression scale (HAD-S). It will be administered at birth, at transition to intermediate care, at NICu discharge at 6 and 12 months corrected age. A score from 0 to 7 is normal, 8-10 borderline and 11-21 score in the clinical range.

up to 12 months corrected age of the infant
Parenting stress
Periodo de tiempo: up to 12 months corrected age of the infant

Assessed with the Parenting Stress Index Scale. Administered at 6 and 12 months corrected age. It is composed of 36 items that are scored on a 5-point Likert scale ranging from 1 (not stressful at all) to 5 (extremely stressful)

up to 12 months corrected age of the infant

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

25 de agosto de 2026

Finalización primaria (Estimado)

1 de junio de 2027

Finalización del estudio (Estimado)

1 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

5 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • EMBRACE

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir